Dr. Dong Xiaoyan, co-founder of Genecradle Therapeutics, attended the 2025 Boao Forum for Asia Annual Conference and shared insights with the media: "Building a health security system for the elderly, women, and children is a crucial task in global health, and the healthy development of the innovative drug industry is the core foundation of this work, which has become a global consensus. The integration of rare disease diagnosis, prevention, and treatment into a healthcare system is of great significance for improving the lifespan of humanity and enhancing people's happiness and sense of gain. The research and launch of innovative rare disease gene therapy drugs represent the latest benchmarks of high-tech industries in this era and are outstanding representatives of new productive forces."

Dr. Dong Xiaoyan's sharing aligns deeply with the theme of this year's Boao sub-forum, "A Shared Future of Health for All." The concept of "solving the dilemma of rare diseases from their root causes," proposed by Genecradle, is being implemented through practice. The GC101 injection for spinal muscular atrophy (SMA) has shown breakthrough advantages of "one-time treatment, long-term efficacy" in clinical trials, and the GC301 injection for Pompe disease, the world's first gene therapy for infantile Pompe disease, has rewritten the history of no effective treatment for children. Genecradle is reshaping the international biopharmaceutical competition landscape with "Made in China" innovation, becoming a benchmark practice example under the "Health Defense Line" agenda at the Boao Forum.

As a core component of the Zhongguancun Forum Annual Conference, the 8th Zhongguancun International Frontier Technology Competition reached its finals and award ceremony on March 28, 2025. This national competition, focusing on cutting-edge fields such as artificial intelligence and life sciences, selects cutting-edge technologies through a "global invitation and free exploration" model. Genecradle's "Disruptive Gene Therapy Platform Technology Project for Children's Critical Genetic Diseases" ranked second in the biopharmaceutical field and made the TOP10 list. The competition judges highly praised its approach of "using platform technology breakthroughs to address bottlenecks in gene therapy industrialization, providing Chinese wisdom for global genetic disease treatment." This award not only highlights Genecradle's research strength but also vividly illustrates the annual theme of the Zhongguancun Forum, "Technology Empowering Industrial Upgrading."

Dr. Wang Qianyi, Head of Public Affairs at Genecradle Therapeutics, represented the company at the forum.

From the global health initiatives at Boao to the technology competition stage at Zhongguancun, Genecradle's "dual appearances" reflect the strong potential of gene therapy as a representative of new productive forces. In the future, Genecradle will always adhere to its quality policy of "Originating from Needs, Benefiting Patients," continue to use innovation as an engine and patients as the center, inject more powerful technological momentum into building a "Healthy China" and a "Global Community of Health," and illuminate the hope for more lives with "Made in China" gene therapy drugs.